SCHEMBL2364152

SCHEMBL2364152

CCOP(=O)(OCC)c1cccc(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
NPSR1 Q6W5P4 1/20 0.47
POLB P06746 2/20 0.45
ALDH1A1 P00352 4/20 0.42
LMNA P02545 2/20 0.42
ACHE P22303 1/20 0.41
CCNT1 O60563 1/20 0.39
CDK9 P50750 1/20 0.39
CA12 O43570 2/20 0.39
CA2 P00918 2/20 0.39
CA5A P35218 2/20 0.39
CA9 Q16790 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
CA1 P00915 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
EGFR P00533 1/20 0.39
LTA4H P09960 1/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12241708 0.84 MEN1 (0.45) MEN1KMT2ANPSR1POLBALDH1A1
SCHEMBL15871416 0.80 NPSR1 (0.48) MEN1KMT2ANPSR1POLBLMNA
SCHEMBL2034316 0.79 NPSR1 (0.47) MEN1KMT2ANPSR1POLBACHE
SCHEMBL916035 0.79 NPSR1 (0.47) MEN1KMT2ANPSR1POLBLMNA
SCHEMBL12229683 0.79 POLB (0.53) MEN1KMT2ANPSR1POLBALDH1A1
SCHEMBL7187605 0.79 NPSR1 (0.47) MEN1KMT2ANPSR1POLBALDH1A1
SCHEMBL4411677 0.79 NPSR1 (0.47) MEN1KMT2ANPSR1POLBACHE
SCHEMBL13636979 0.79 NPSR1 (0.47) MEN1KMT2ANPSR1POLBALDH1A1
SCHEMBL4423591 0.79 NPSR1 (0.47) MEN1KMT2ANPSR1POLBALDH1A1
SCHEMBL31688379 0.79 NPSR1 (0.47) MEN1KMT2ANPSR1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2348857-B1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME (US) 2016-02-24 EP disclosed
US-8410284-B2 Cyclic benzimidazole derivatives useful as anti-diabetic agents MERCK SHARP & DOHME CORP (US) 2013-04-02 US disclosed
US-20110263533-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. 2011-10-27 US disclosed
EP-2348857-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS Merck Sharp & Dohme Corp. (US) 2011-08-03 EP disclosed
WO-2010047982-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263533-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 MEN1 3565/4885KMT2A 2171/4885NPSR1 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.